Search

everythinglearnresearchcommunity

for

Search:↓

The user has been treating hair loss with finasteride, dutasteride, oral minoxidil, and pyrilutamide for several years without success and is experiencing an inflamed scalp, possibly due to seborrheic dermatitis. They are seeking advice on additional treatments after these methods failed to improve their condition.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

21-year-old female experiencing hair loss and visible scalp seeks advice on PRP effectiveness. Currently taking spironolactone and krimson for high androgens, unsure if PRP can be done with these medications.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.

A user asked if olive oil can replace propylene glycol or glycerin in topical finasteride preparation. Another user advised against it, suggesting MCT oil instead due to olive oil's potential to worsen dandruff and seborrheic dermatitis.

The user is using minoxidil, topical finasteride, Nizoral shampoo, and a dermaroller for hair regrowth but is experiencing changes in sexual function. They are concerned about whether these changes are due to the treatment and are seeking advice on continuing hair growth without affecting sexuality.

User experienced hair regrowth after eliminating scalp itch with RU58841. Others discussed itch and hair loss connection, and effectiveness of combining RU58841 with 5AR inhibitors.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

A 27-year-old man shared his 10-month hair regrowth progress after taking oral finasteride, noting initial hair shedding followed by noticeable thickening around 5-6 months, with significant improvement by March. He also mentioned having scalp psoriasis.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

A 29-year-old male experienced hair regrowth using minoxidil 5% foam and KX826 after stopping finasteride due to side effects. He applies both treatments once daily and reports no side effects from the current regimen.

The user is experiencing increased hair loss and was diagnosed with male pattern baldness. They are considering using oral or topical finasteride to manage the condition and are contemplating cutting their hair short.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

User is using a homemade topical treatment with .015% finasteride, 5% minoxidil, and microneedling at .75mm depth. They also use 2% ketoconazole shampoo, various oils, and are considering increasing finasteride concentration due to mixed results.

The conversation discusses whether using 0.1% topical finasteride alongside 0.5 mg oral finasteride is excessive, with suggestions to choose either oral or topical treatment. The user also uses 5% minoxidil and mentions concerns about alcohol-based solutions due to seborrheic dermatitis.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

The conversation discusses using RU58841 or Pyrilutamide for hair loss, with some users suggesting switching to more proven treatments like oral or topical finasteride. One user reports no progress with RU58841, finasteride, and minoxidil, and mentions experiencing regression.

A 21-year-old is concerned about androgenic alopecia and has been using minoxidil for a year, noticing some stabilization in the hairline but fears using it on the whole scalp due to seborrheic dermatitis. Another person suggests considering a psychiatrist for stress management, using Nizoral shampoo, and possibly trying a small dose of finasteride.

Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

The user is using finasteride, minoxidil, and ciclopirox shampoo for hair loss and is considering adding a topical anti-androgen like RU58841, Clacosterone, or KX286. They have scheduled a hair transplant and are concerned about the cost and effectiveness of future treatments.

The user is experiencing white flakes and a greasy look from using a topical solution containing 0.025% finasteride, 8% minoxidil, 0.01% retinoic acid, and 1% hydrocortisone. Suggestions include reducing application frequency, using a brush to clean the scalp, and considering alcohol-free alternatives.

The conversation discusses the effectiveness of anti-androgens for hair loss, with a preference for topical treatments like RU58841 over oral options due to better scalp concentration and fewer side effects. Topical finasteride at 0.1% may provide some results, especially when combined with a topical androgen receptor antagonist like RU58841.

The user experienced sexual side effects from a topical finasteride and minoxidil combo and stopped using it after three weeks. They plan to use foam minoxidil nightly to slow hair loss and seek alternative treatments that don't affect sexual health.

Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.

The user experienced hair regrowth using finasteride, oral and topical minoxidil, and RU58841, despite initial shedding. They also transitioned from finasteride to dutasteride and addressed scalp issues with a folliculitis shampoo.

The user has been using topical minoxidil (5%) for two years and kx826/pyrilutamide for one year, after experiencing side effects from finasteride. They report positive results from the combination of minoxidil and kx826 in combating hair loss.

After nearly four months on finasteride, a user noticed improved hair quality but developed nipple puffiness, suggesting early signs of gynecomastia. They considered switching to other treatments like CB-03-01 or RU58841 and contemplated consulting an endocrinologist about aromatase inhibitors.